The FDA has approved Eli Lilly’s Mounjaro to reduce the risk of major adverse cardiovascular events in adults with Type 2 diabetes. This authorization expands the medication’s existing label, which already covers lowering blood sugar in adults and children over the age of 10. The new approval specifically targets the prevention of cardiovascular death, non-fatal heart attacks, and non-fatal strokes.
The decision rests on results from the SURPASS-CVOT trial. This phase 3 study enrolled a large cohort of over 13,000 patients across 30 international countries. Investigators tracked these individuals for more than four years. The primary objective was to demonstrate that Mounjaro provided a non-inferior reduction in the risk of major adverse cardiovascular events compared to Trulicity, another GLP-1 treatment from the same company. SURPASS-CVOT successfully met this goal. In fact, the data indicated an 8 percent lower rate of cardiovascular death, heart attack, or stroke compared to the control group.
Mounjaro has become a major commercial success for the manufacturer. In the first half of 2026, the drug generated $18.6 billion in sales, a significant increase from the prior year. Zepbound has also seen rapid adoption, bringing in billions in revenue. For patients accessing the therapy, the wholesale acquisition cost sits at $1,112.16. Lilly provides financial assistance options for those with commercial insurance. Eligible patients may pay as little as $25 for a three-month supply.
Related: Murray Discusses ACA Marketplace Shifts and Nonnetwork Plans
Safety data from the trial indicates that the most common adverse events were gastrointestinal-related. These side effects were generally mild to moderate in severity and occurred primarily during the dose-escalation period. Lilly is not resting on these results alone. The company is conducting an observational claims study to further understand the medication’s long-term effects. This new research will compare new users of tirzepatide against new users of dulaglutide or semaglutide. The focus is on adults 40 and older with established atherosclerotic cardiovascular disease. The study will assess outcomes like myocardial infarction, stroke, and all-cause mortality over a follow-up period of up to four years.
Many glucose-lowering agents have failed to prevent heart attacks.
For decades, the treatment of Type 2 diabetes has largely focused on glycemic control. Cardiovascular risk was often viewed as a separate, downstream issue. This new approval is significant because it demonstrates that a dual agonist therapy can successfully manage both metabolic and circulatory risks simultaneously. Unlike older drugs that targeted single pathways, this approach addresses the complex interplay between glucose levels and heart health, offering a more holistic solution for patients at high risk of cardiovascular events.
Related: FDA approves first-of-its-kind therapy for metastatic pancreatic cancer
Dr. David A. D’Alessio, the study co-author and director of the Division of Endocrinology and Metabolism at Duke University School of Medicine, emphasized that while glucose control is a major part of diabetes care, mitigating cardiovascular risk is essential.
He stated that this approval gives patients a medicine that reduces the risk of cardiovascular events and supports metabolic health at the same time.
